Brookwood Investment Group LLC Invests $234,000 in Lam Research Corporation $LRCX

Brookwood Investment Group LLC acquired a new position in shares of Lam Research Corporation (NASDAQ:LRCX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,406 shares of the semiconductor company’s stock, valued at approximately $234,000.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its position in Lam Research by 6.9% during the first quarter. Vanguard Group Inc. now owns 129,152,102 shares of the semiconductor company’s stock worth $9,389,358,000 after acquiring an additional 8,364,375 shares during the last quarter. Nuveen LLC acquired a new stake in Lam Research during the first quarter worth approximately $604,344,000. Price T Rowe Associates Inc. MD boosted its position in Lam Research by 99.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,739,221 shares of the semiconductor company’s stock worth $417,242,000 after acquiring an additional 2,864,863 shares during the last quarter. Nordea Investment Management AB boosted its position in Lam Research by 34.1% during the second quarter. Nordea Investment Management AB now owns 10,594,574 shares of the semiconductor company’s stock worth $1,029,210,000 after acquiring an additional 2,692,189 shares during the last quarter. Finally, Boston Partners boosted its position in Lam Research by 9,978.3% during the first quarter. Boston Partners now owns 2,350,362 shares of the semiconductor company’s stock worth $170,787,000 after acquiring an additional 2,327,041 shares during the last quarter. 84.61% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on LRCX shares. Cowen restated a “buy” rating on shares of Lam Research in a research report on Thursday, October 23rd. HSBC set a $127.00 price target on shares of Lam Research and gave the company a “hold” rating in a report on Tuesday, September 30th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Lam Research in a report on Wednesday, October 8th. Needham & Company LLC lifted their price target on shares of Lam Research from $150.00 to $160.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Finally, Citigroup lifted their price target on shares of Lam Research from $120.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-six have issued a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $148.83.

Insider Buying and Selling at Lam Research

In other news, insider Ava Harter sold 9,010 shares of the business’s stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $157.47, for a total value of $1,418,804.70. Following the completion of the sale, the insider owned 56,786 shares of the company’s stock, valued at approximately $8,942,091.42. The trade was a 13.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Vahid Vahedi sold 52,190 shares of the business’s stock in a transaction dated Monday, October 13th. The stock was sold at an average price of $138.90, for a total transaction of $7,249,191.00. Following the completion of the sale, the senior vice president directly owned 251,047 shares of the company’s stock, valued at $34,870,428.30. The trade was a 17.21% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.31% of the company’s stock.

Lam Research Stock Performance

NASDAQ:LRCX opened at $155.62 on Wednesday. The company has a current ratio of 2.21, a quick ratio of 1.60 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $195.46 billion, a price-to-earnings ratio of 34.28, a PEG ratio of 1.64 and a beta of 1.84. The firm’s fifty day simple moving average is $125.50 and its 200 day simple moving average is $101.30. Lam Research Corporation has a twelve month low of $56.32 and a twelve month high of $158.24.

Lam Research (NASDAQ:LRCX) last posted its earnings results on Wednesday, October 22nd. The semiconductor company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.04. The business had revenue of $5.32 billion for the quarter, compared to analyst estimates of $5.23 billion. Lam Research had a net margin of 29.66% and a return on equity of 60.60%. The business’s quarterly revenue was up 27.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.86 EPS. Lam Research has set its Q2 2026 guidance at 1.050-1.250 EPS. As a group, equities research analysts expect that Lam Research Corporation will post 3.71 earnings per share for the current fiscal year.

Lam Research Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 15th. Investors of record on Wednesday, September 24th were paid a dividend of $0.26 per share. This is a positive change from Lam Research’s previous quarterly dividend of $0.23. The ex-dividend date of this dividend was Wednesday, September 24th. This represents a $1.04 annualized dividend and a yield of 0.7%. Lam Research’s payout ratio is presently 22.91%.

Lam Research Profile

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.